S2107 Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment
Billable / valid for submission HCPCS Release 2026Q3
Short description: Adoptive immunotherapy
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment | yes |
Related codes in S21
- S2102 Islet cell tissue transplant from pancreas; allogeneic
- S2103 Adrenal tissue transplant to brain
- S2112 Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)
- S2115 Osteotomy, periacetabular, with internal fixation
- S2117 Arthroereisis, subtalar
- S2118 Metal-on-metal total hip resurfacing, including acetabular and femoral components
- S2120 Low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitation
- S2140 Cord blood harvesting for transplantation, allogeneic
- S2142 Cord blood-derived stem-cell transplantation, allogeneic
- S2150 Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition
- S2152 Solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor(s), procurement, transplantation, and related complications; including: drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre- and post-transplant care in the global definition